
Vaccine Makers are Working to Determine how well the Current Vaccine Formulations hold up Against Omicron

the staff of the Ridgewood blog
Ridgewood NJ, Rutgers, Fairleigh Dickinson, Princeton and Montclair State University now all require students to be fully vaccinated from COVID19 by the start of their fall semesters. The rule stands for all students attending classes on-campus, whether residing in a dorm or commuting to school.
the staff of the Ridgewood blog
Ridgewood NJ, The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation.
the staff of the Ridgewood blog
Ridgfewood NJ, according to Village Manager Heather A. Mailander on December 10, 2020 the Village of Ridgewood Health Department was certified by the State of NJ to operate a Covid19 Vaccine Clinic. The authorization was a result of months of planning, filing of required paperwork, and ensuring appropriate staffing. Ridgewood was able to achieve approval because the Village maintains a local health department.
Continue reading RIDGEWOOD HEALTH DEPARTMENT COVID19 VACCINE CLINIC
Continue reading Johnson & Johnson (J&J) published preliminary findings for COVID19 Vaccine
the staff of the Ridgewood blog
Oxford UK, The Phase 3 clinical trial for AstraZeneca’s candidate SARS-CoV-2 vaccine (developed in collaboration with Oxford University) has been paused following the identification of a serious adverse event in one of the participants. Neither AstraZeneca nor Oxford University have yet disclosed details of the adverse event, which reportedly occurred in the UK; however, The New York Times reports that the patient developed transverse myelitis. It has not yet been determined whether the condition was associated with the vaccine. An earlier clinical trial for the AstraZeneca vaccine was also paused following the diagnosis of transverse myelitis in a participant, but the trial resumed after a safety review determined that the condition was not related to the vaccine.
Continue reading AstraZeneca’s COVID19 Vaccine Trial Paused Over Safety Concerns
the staff of the Ridgewood blog
Ridgewood NJ, AstraZeneca COVID19 vaccine expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity.1
The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, and led by AstraZeneca. The NIAID-supported COVID-19 Prevention Network (CoVPN) will participate in the trial.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “We are pleased that AZD1222 demonstrated safety and immunogenicity across all adult age groups and are proud to be collaborating with BARDA and NIAID to accelerate the development of this vaccine. Should clinical trials demonstrate the vaccine protects against COVID-19 disease and is approved for use, we will work hard to make it globally available in a fair and equitable manner as rapidly as possible.”